Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
L Imran, R Zubair, S Mughal… - Annals of Medicine and …, 2023 - journals.lww.com
Nirmatrelvir boosted with Ritonavir is the recommended and preferred treatment for COVID-
19. Because real-world evidence of Nirmatrelvir's antiviral activity against the Omicron …
19. Because real-world evidence of Nirmatrelvir's antiviral activity against the Omicron …
[HTML][HTML] Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA. 5 and BN. 1 subvariant dominance in the Republic of Korea: a …
DH Kim, MG Yoo, NY Kim, SY Choi… - Osong Public Health …, 2024 - ncbi.nlm.nih.gov
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment
in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and …
in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk …
Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …
Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
D Paraskevis, M Gkova, K Mellou… - The Journal of …, 2023 - academic.oup.com
Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
[HTML][HTML] A Retrospective Study on COVID-19 Infections Caused by Omicron Variant with Clinical, Epidemiological, and Viral Load Evaluations in Breakthrough …
J Liu, R Wen, N Wang, G Li, P Xu, X Li… - International Journal of …, 2024 - ncbi.nlm.nih.gov
Purpose: To explore the clinical, epidemiological, and viral load characteristics of COVID-19
caused by the omicron variant. Methods: Based on the COVID-19 epidemic caused by …
caused by the omicron variant. Methods: Based on the COVID-19 epidemic caused by …
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study
AA Butt, P Yan, OS Shaikh, VB Talisa… - The Journal of …, 2024 - academic.oup.com
Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization
or death within 30 days as compared with untreated controls previously uninfected and …
or death within 30 days as compared with untreated controls previously uninfected and …
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
Y Wang, D Zhao, X Chen, X Liu… - Influenza and other …, 2023 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients
K Cowman, A Miller, Y Guo, MH Chang… - Journal of …, 2023 - academic.oup.com
Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …
Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
Y Zhang, X Wang, C Huang, H Yang… - Infection and Drug …, 2024 - Taylor & Francis
Objective The efficacy of nirmatrelvir–ritonavir for hospitalized patients with COVID-19 has
not been fully established. Methods We conducted a retrospective analysis of hospitalized …
not been fully established. Methods We conducted a retrospective analysis of hospitalized …